Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.

Publication

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.

Journal Paper/Review - Jun 29, 2023

D'Haens Geert, Dubinsky Marla, Kobayashi Taku, Irving Peter M, Howaldt Stefanie, Pokrotnieks Juris, Krueger Kathryn, Laskowski Janelle, Li Xingyuan, Lissoos Trevor, Milata Joe, Morris Nathan, Arora Vipin, Milch Catherine, Sandborn William J, Sands Bruce E, LUCENT Study Group, Brand Stephan

Citation

D'Haens G, Dubinsky M, Kobayashi T, Irving P, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands B, LUCENT Study Group, Brand S. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2023; 388:2444-2455.

Type

Journal Paper/Review (English)

Journal

N Engl J Med 2023; 388

Publication Date

Jun 29, 2023

Issn Electronic

1533-4406

Pages

2444-2455

Brief description/objective

Mirikizumab, a p19-directed antibody against interleukin-23, showed efficacy in the treatment of ulcerative colitis in a phase 2 trial.